By: Angus Liu
Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.
Angus Liu is a Senior Staff Writer for Fierce Pharma, specializing in biopharma news and developments. With a background in journalism from Medill School of Journalism, Angus covers topics such as regulatory updates, drug launches, clinical trials, and industry trends. His work has been featured in Fierce Biotech as well, showcasing his expertise in the biotechnology sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .